Elena Vendrame, MD
Infectious Disease · Mountain View
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 1 carrier
- Offices
- 2
Offices
2 locations
Looking this up.
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plans that list them
12 plans · 1 carrier
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Vendrame’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Silicon (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health smartHMO (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health the ONE (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
California Medical Board record
Licence A129667 · Current
Licensed to practise in California · since 2014 · expires 2028-04-30 · University of Padua Faculty of Medicine and Surgery.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$3,786
Medicare paid this office $3,786 for 14 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
Who their Medicare patients are
14 Original Medicare patients in 2024. Average age 66 · 85 and older 0% · Health risk score 1.13. At or below the middle of the specialty; the typical infectious disease clinician is at 3.
The office billed $12,878, Medicare allowed $5,139 and paid $3,786; for 41 services of 4 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 14 | 41 | 66 | 1.13 | $12,878 | $3,786 |
| 2023 | 15 | 25 | 66 | 2.65 | $5,676 | $1,941 |
| 2021 | 13 | 35 | 65 | 1.84 | $10,637 | $2,337 |
| 2020 | 39 | 99 | 68 | 2.76 | $31,055 | $7,306 |
| 2019 | 104 | 213 | 72 | 2.72 | $56,869 | $20,349 |
| 2018 | 60 | 115 | 76 | 3.38 | $37,063 | $11,442 |
| 2017 | 52 | 107 | 74 | 3.69 | $32,641 | $10,198 |
| 2016 | 30 | 59 | 71 | 2.72 | $17,065 | $5,428 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2020: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 13 | $2,932 | $101 |
| Return visit (30+ min) | 15 | $1,275 | $55 |
2019: 5 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 46 | $7,009 | $95 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 25 | $4,607 | $184 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 36 | $3,447 | $66 |
| Long return visit (40+ min) | 17 | $2,884 | $99 |
| Return visit (30+ min) | 13 | $1,441 | $66 |
2018: 3 services
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 22 | $4,184 | $182 |
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 23 | $3,745 | $94 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 33 | $3,269 | $65 |
2017: 3 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 25 | $3,803 | $93 |
| Initial hospital care with moderate level of medical decision making at least 75 minutes | 19 | $3,445 | $181 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 27 | $2,826 | $63 |
2016: 2 services
| Subsequent hospital care with moderate levelof medical decision making at least 50 minutes | 12 | $1,574 | $93 |
| Subsequent hospital care with moderate levelof medical decision making at least 35 minutes | 14 | $1,543 | $64 |
Drugs they prescribed that Part D paid
$220,157
Pharmacies billed $220,157 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 205) in 2024. At or below the middle of the specialty; the typical infectious disease clinician is at 0%.
135 generic and 70 brand-name prescriptions · $220,157 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Biktarvy | 18 | $70,759 | $3,931 |
| Triumeq | 13 | $55,544 | $4,273 |
| Prezcobix | 18 | $48,189 | $2,677 |
| Trazodone | 18 | $87 | $5 |
| Metformin Hcl Er | 14 | $54 | $4 |
See all 6 drugs
| Biktarvy | 18 | $70,759 | $3,931 |
| Triumeq | 13 | $55,544 | $4,273 |
| Prezcobix | 18 | $48,189 | $2,677 |
| Trazodone | 18 | $87 | $5 |
| Metformin Hcl Er | 14 | $54 | $4 |
| Atorvastatin | 13 | $53 | $4 |
Year by year
| 2024 | 205 | 15 | 0% (0) | 34% | $220,157 |
| 2023 | 132 | None | None | 49% | $148,120 |
| 2022 | 69 | None | 0% (0) | 23% | $43,992 |
| 2021 | 185 | 19 | None | 35% | $170,534 |
| 2020 | 564 | 37 | 7% (39) | 33% | $388,773 |
| 2019 | 378 | 32 | 12% (45) | 37% | $284,332 |
| 2016 | 38 | None | None | 29% | $13,769 |
| 2015 | 13 | None | 0% (0) | None | $3,315 |
| 2014 | 407 | 51 | None | 27% | $24,981 |
| 2013 | 353 | 64 | None | 15% | $19,151 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 3 drugs
| Biktarvy | 22 | $89,983 | $4,090 |
| Gabapentin | 11 | $125 | $11 |
| Levothyroxine | 11 | $51 | $5 |
2021: 2 drugs
| Biktarvy | 32 | $117,018 | $3,657 |
| Testosterone | 11 | $1,399 | $127 |
2020: 16 drugs
| Biktarvy | 25 | $105,200 | $4,208 |
| Descovy | 36 | $67,866 | $1,885 |
| Triumeq | 11 | $50,914 | $4,629 |
| Symtuza | 12 | $47,260 | $3,938 |
| Truvada | 12 | $22,951 | $1,913 |
| Tivicay | 11 | $20,511 | $1,865 |
| Ritonavir | 13 | $1,915 | $147 |
| Potassium Citrate Er | 12 | $1,826 | $152 |
| Morphine Sulfate | 14 | $736 | $53 |
| Gabapentin | 32 | $523 | $16 |
| Levothyroxine | 25 | $450 | $18 |
| Sulfamethoxazole-Trimethoprim | 11 | $270 | $25 |
| Lisinopril | 30 | $144 | $5 |
| Atorvastatin | 16 | $108 | $7 |
| Metformin | 15 | $61 | $4 |
| Losartan | 11 | $31 | $3 |
2019: 9 drugs
| Triumeq | 18 | $85,150 | $4,731 |
| Biktarvy | 21 | $65,687 | $3,128 |
| Truvada | 14 | $23,992 | $1,714 |
| Tivicay | 13 | $22,669 | $1,744 |
| Gabapentin | 30 | $941 | $31 |
| Morphine Sulfate | 11 | $604 | $55 |
| Levothyroxine | 16 | $220 | $14 |
| Metformin | 25 | $93 | $4 |
| Lisinopril | 12 | $59 | $5 |
2016: 2 drugs
| Sustiva | 11 | $10,303 | $937 |
| Lamivudine Hbv | 11 | $3,321 | $302 |
2014: 10 drugs
| Lantus | 16 | $3,461 | $216 |
| Crestor | 12 | $2,563 | $214 |
| Atorvastatin | 49 | $636 | $13 |
| Pantoprazole | 11 | $249 | $23 |
| Lisinopril | 27 | $149 | $6 |
| Losartan | 21 | $125 | $6 |
| Amlodipine Besylate | 27 | $92 | $3 |
| Atenolol | 17 | $80 | $5 |
| Metformin | 14 | $79 | $6 |
| Hydrochlorothiazide | 14 | $28 | $2 |
2013: 8 drugs
| Atorvastatin | 25 | $747 | $30 |
| Nifedical Xl | 13 | $388 | $30 |
| Omeprazole | 34 | $379 | $11 |
| Metformin | 19 | $136 | $7 |
| Simvastatin | 11 | $100 | $9 |
| Lisinopril | 18 | $96 | $5 |
| Amlodipine Besylate | 16 | $58 | $4 |
| Atenolol | 11 | $57 | $5 |
Money from drug and device companies
$33 in 2024
A payment is not proof that care is biased.
| Gilead Sciences | None | $33 | 1 payment
|
See the published payment
| Gilead Sciences | Meals · 2024-04-02 | None | $33 |
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 76.5 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1598059594
- Licence
- CA A129667California A129667: Current · expires 2028-04-30
- Video visits
- Lists video visits
- Gender
- Female
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207RI0200X (207RI0200X); Internal medicine (207R00000X)
- Mailing address
- 300 Pasteur Dr, Stanford, CA, 94305
- NPI first listed
- 2011-06-07
- NPI last updated
- 2024-04-17
- NPI record certified
- 2024-04-17
This is when the NPI record was last certified, not a medical board exam.